Divis Laboratories Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f32ulcf7464se9bxbisxzhej.pdf

Key Takeaways


Custom Synthesis: The Growth Engine Firing

Dr. Murali K Divi: "The Custom Synthesis growth is not just one company or one product, it is distributed over several therapeutic segments."

GLP-1: The Next Growth Engine

Dr. Murali K Divi: "The opportunity is like another growth engine, you are right. It's not a small opportunity. It can be even bigger than a single growth engine."

Generic APIs: Volume Healthy, Pricing Weak

Nilima Divi: "The volume is there. It's just that the pricing is lower, so that's when you're seeing the revenue is moderately more than what it was last year."

Margins: Hit by Generics Pricing and One-off Costs


Strategic Positioning & Capacity

Dr. Murali K Divi: "For a stable player like ours, it should not matter. We don't disappear when the price comes down and we don't appear when the price increases by 20%."

Guidance & Commitments

CommitmentSpecificsTimeline
Unit 3 Phase I production startCommence production activitiesEnd of Q1 FY25
Generic pricing stabilizationPricing pressure in large-volume generics to settleComing quarters
GLP-1 building blocks revenueSome value visible, then very large volumesLight toward FY25; large volumes after qualifications
Gadolinium-based contrast media suppliesCustomer qualifications and samples firstMore toward FY25 than this fiscal
Custom Synthesis revenue visibilityMore clarity expectedFrom Q3 FY24
DMF-driven growth contributionRecently filed DMFs to contributeBeyond FY25
Inventory destocking cycle durationNot more than 2 years per cyclePer historical pattern

Key Metrics

MetricQ2 FY24
Consolidated total income₹1,995 cr, vs ₹1,935 cr in Q2 FY23 and ₹1,859 cr in Q1 FY24
Ex-Covid portfolio growthDouble-digit YoY for the quarter and half year
Constant currency growthNegative 1% for the quarter
Profit before tax₹469 cr for the quarter
Profit after tax₹348 cr for the quarter
Material consumption42% of revenue, higher due to product mix and pricing pressure
Forex gain₹11 cr, vs ₹31 cr gain in Q2 FY23
Exports share87% of total income
Exports to Europe and U.S.68% of total income
Generics to Custom Synthesis mix60:40 for the quarter
Nutraceutical business revenue₹205 cr for the quarter
Carotenoid products sales growth~15% increase this quarter
Inventory write-off₹20 cr, related to leftover COVID drug materials
Capital work in progress₹496 cr as of end September 2023, of which Kakinada project is ₹263 cr
Cash on books₹3,604 cr as of 30th September 2023
Receivables₹1,858 cr as of 30th September 2023
Inventories₹2,969 cr as of 30th September 2023